Use of driving-impairing medicines by a Spanish population: a population-based registry study

Eduardo Gutierrez-Abejón,1 Francisco Herrera-Gómez,2,3 Paloma Criado-Espegel,1 F Javier Alvarez2,4

ABSTRACT

Objective To assess the use of driving-impairing medicines (DIM) in the general population with special reference to length of use and concomitant use.

Design Population-based registry study.

Setting The year 2015 granted medicines consumption data recorded in the Castile and León (Spain) medicine dispensation registry was consulted.

Participants Medicines and DIM consumers from a Spanish population (Castile and León: 2.4 million inhabitants).

Exposure Medicines and DIM consumption. Patterns of use by age and gender based on the length of use (acute: 1–7 days, subacute: 8–29 days and chronic use: ≥30 days) were of interest. Estimations regarding the distribution of licensed drivers by age and gender were employed to determine the patterns of use of DIM.

Results DIM were consumed by 34.4% (95% CI 34.3% to 34.5%) of the general population in 2015, more commonly with regularity (chronic use: 22.5% vs acute use: 5.3%) and more frequently by the elderly. On average, 2.3 DIM per person were dispensed, particularly to chronic users (2.8 DIM per person). Age and gender distribution differences were observed between the Castile and León medicine dispensation registry data and the drivers’ license census data. Of all DIM dispensed, 83.8% were in the Anatomical Therapeutic Chemical code group nervous system medicines (N), which were prescribed to 29.2% of the population.

Conclusions The use of DIM was frequent in the general population. Chronic use was common, but acute and subacute use should also be considered. This finding highlights the need to make patients, health professionals, health providers, medicine regulatory agencies and policy-makers at large aware of the role DIM play in traffic safety.

BACKGROUND

Driving a motor vehicle is a multifaceted task and requires appropriate cognitive and psychomotor skills (eg, alertness, concentration, reaction time and visual acuity).1 2 Medicines can adversely affect these driving-related skills and, consequently be a hazard to traffic safety.3 5 There is increasing awareness that implementation of appropriate measures to limit the consumption of alcohol and other substances (‘illicit’ drugs and medicines) while driving may have an impact on road accident occurrences.6 Nevertheless, to date, it is unknown how frequent the consumption of driving-impairing medicines (DIM) in the general population is, or how frequently several of these drugs are consumed concomitantly.7

Conversely, most developed countries perform toxicological analyses on road accident casualties and fatalities, and the presence of illicit drugs and medicines (either used legally or illegally) are detected.8 9 On-road tests (at random or on target populations) are used ever more frequently worldwide: the on-site screening devices detect some groups of illicit drugs and certain medicines in saliva (oral fluid), with confirmation analyses being performed later.8 9 In other countries, blood analyses10 are performed, rather than screening of saliva. The information from these sources (data on casualties/fatalities and on-road test data) gives only a partial vision of the problem regarding medicines and driving.11

However, medicine regulatory agencies do attempt to provide appropriate information...
to the public concerning the problem: in the European Union, the summary of product characteristics and the package leaflets contain information on medicines that ‘affect the ability to drive and to use machines’. Furthermore, there have been several attempts to categorise the effects of medicines on driving and several countries, such as France and Spain, have introduced specific mandatory pictograms or ancillary warning labels, as in the Netherlands and Australia.

The Spanish Law of 2007 (Royal Decree 1345/2007) established the rule that newly authorised medicines that may negatively affect fitness to drive or to handle dangerous machinery should include a warning symbol (pictogram) on the outside of the packaging. Since 2011, all medicines that could possibly affect fitness to drive and are commercially available in Spain have this pictogram on the packaging. As of January 2016, a total of 2015 medicinal drugs permitted in Spain had been reviewed, of which 402 (20%) included the pictogram on medicines and driving on the packaging. This pictogram is well regarded by the population.

We have considered these medicines with the pictogram ‘medicines and driving’ on the packaging in Spain as DIM or, to be more exact, potentially impairing medicines on driving. In 2016, a national consensus on medicines and driving was reached in Spain to determine the extent of the population taking DIM as a priority and to decipher patterns of use for these drugs. This did not apply only to motor vehicle drivers and professional drivers but also to the population at large, as well as to all road users, including pedestrians and the ever more common cyclists. Thus, the presence of illicit drugs and medicines was also frequently found in pedestrians involved in fatal road accidents.

The detection of some medicines in on-road tests has been the object of awareness raising in public and health professionals, as well as the subject of campaigns to inform the general public, as in the UK. In some countries, for instance, the UK, Spain or Norway, on-road positive cases to medicines are not fined if they were used according to a physician’s prescription. Again, it is necessary that the consumption of DIM and their patterns of use should be known in detail, given that there is a shortage of information about this.

Fitness to drive evaluations has been applied in most developed countries, although the procedures differ markedly. Across the European Union, there is a minimum common regulation under Council Directive 439/EEC. Within the context of a fitness to drive evaluation, an issue to be considered is medication use (prescribed and over-the-counter) by the driver, although this should always be assessed under the complex relationship between disease and medication, particularly among aged people who frequently suffer from several diseases and are polymedicated.

Consequently, the aim of our study was to explore the use of DIM by the general population. The consumption of medicines with the pictogram ‘medicines and driving’ was assessed on the basis of our dispensation registry, focusing on concomitant use of these drugs and on their length of use. In addition, estimations were compared with the drivers’ license census to determine the patterns of use among drivers.

METHODS
Study population: CONCYLIA database
Access was provided to the CONCYLIA database to assess the dispensation of granted medicines by the Spanish public health system in Castile and León during 2015.

Basically, the CONCYLIA database includes information on all medicine dispensations by the public health system, except those dispensed at hospitals, medical prescriptions dispensed through private medicine clinics and those that do not require a medical prescription (‘over-the-counter’ medications).

We assessed medicine dispensation per person using the patient identification number; that is, for each person, any dispensation during 2015 was identified (eg, medicinal product, number of doses and data of dispensation). For data protection, the final database provided by the health system was anonymised, and no personal identification was included.

Target population
The population distribution covered by the public health system and the population distribution according to the population census matched well: Castile and León had a population of 2 428 901 in December 2015, and 2 376 717 were covered by the public health system at that time (97.85% of the total).

The current target population of the study was the general population at large. However, not all persons had a motor vehicle license or drove motor vehicles. Due to the lack of information on driving recorded in the CONCYLIA database, weighting was performed to adjust consumption of DIM of the general population to licensed drivers by age and gender based on the Castile and León drivers’ license census data up to December 2015. Therefore, the results are presented in regard to the general population and/or as estimates of the driver population based on weighting to the drivers’ license census data (table 1).

Driving-Impairing Medicines
As mentioned above, granted medicines in Spain with the pictogram ‘medicines and driving’ were considered as DIM.

In the CONCYLIA database, based on the Anatomical Therapeutic Chemical code (ATC), each one of the medicines is identified as having such a pictogram or not. This information was taken from the Spanish Medicine Agency, updated to 1 February 2016.

Variables and ethical issues
The following variables describing the consumption of medicines and DIM in Castile and León in the year 2015...
### Table 1 Data on consumption of medicines according to the CONCYLIA database and drivers’ license census

<table>
<thead>
<tr>
<th>Age range (Male/Female)</th>
<th>Population in Castile and León with health insurance card (December 2015)</th>
<th>Drivers’ license census (December 2015)</th>
<th>All medicines % (95% CI)</th>
<th>Medicines with the pictogram ‘medicines and driving’ % (95% CI)</th>
<th>Drivers using medicines with the pictogram ‘medicines and driving’ % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–4</td>
<td>45 405/42 504</td>
<td>–</td>
<td>76.59/74.86</td>
<td>15.61/15.31</td>
<td>0.52/0.43</td>
</tr>
<tr>
<td>5–9</td>
<td>50 925/48 078</td>
<td>–</td>
<td>71.22/69.60</td>
<td>6.82/7.05</td>
<td>2.73/1.50</td>
</tr>
<tr>
<td>15–19</td>
<td>48 620/46 904</td>
<td>9 282/5 586</td>
<td>62.49/68.16</td>
<td>3.17/4.18</td>
<td>7.06/5.33</td>
</tr>
<tr>
<td>20–24</td>
<td>54 724/53 382</td>
<td>43 294/35 87</td>
<td>53.00/67.78</td>
<td>3.48/4.77</td>
<td>4.51/5.87</td>
</tr>
<tr>
<td>25–29</td>
<td>62 787/61 247</td>
<td>55 831/50 618</td>
<td>47.83/65.06</td>
<td>3.51/5.06</td>
<td>4.81/7.23</td>
</tr>
<tr>
<td>30–34</td>
<td>75 089/71 664</td>
<td>69 810/61 387</td>
<td>46.72/66.41</td>
<td>3.51/5.27</td>
<td>6.02/9.44</td>
</tr>
<tr>
<td>35–39</td>
<td>90 372/87 031</td>
<td>86 841/75 838</td>
<td>50.20/68.35</td>
<td>3.95/5.20</td>
<td>7.84/12.28</td>
</tr>
<tr>
<td>40–44</td>
<td>92 686/89 979</td>
<td>89 294/76 277</td>
<td>54.63/69.28</td>
<td>4.10/5.27</td>
<td>10.12/16.23</td>
</tr>
<tr>
<td>45–49</td>
<td>93 082/91 643</td>
<td>90 151/74 310</td>
<td>59.23/72.04</td>
<td>4.32/5.47</td>
<td>12.90/20.68</td>
</tr>
<tr>
<td>50–54</td>
<td>93 250/90 618</td>
<td>90 450/67 282</td>
<td>66.50/77.55</td>
<td>4.87/5.83</td>
<td>16.37/25.63</td>
</tr>
<tr>
<td>55–59</td>
<td>87 280/84 212</td>
<td>85 820/56 346</td>
<td>74.43/82.71</td>
<td>5.09/5.83</td>
<td>20.38/31.45</td>
</tr>
<tr>
<td>60–64</td>
<td>72 448/69 337</td>
<td>71 450/36 255</td>
<td>82.67/87.96</td>
<td>5.57/5.98</td>
<td>25.65/37.38</td>
</tr>
<tr>
<td>65–69</td>
<td>65 430/66 777</td>
<td>62 572/23 964</td>
<td>89.09/91.10</td>
<td>5.88/5.90</td>
<td>31.21/43.95</td>
</tr>
<tr>
<td>70–74</td>
<td>56 526/61 968</td>
<td>51 161/12 390</td>
<td>93.79/94.39</td>
<td>5.86/5.55</td>
<td>38.05/52.02</td>
</tr>
<tr>
<td>75–79</td>
<td>45 154/56 939</td>
<td>35 993/5 000</td>
<td>93.34/93.00</td>
<td>5.76/4.74</td>
<td>44.10/58.52</td>
</tr>
<tr>
<td>80–84</td>
<td>44 543/62 354</td>
<td>28 304/1 941</td>
<td>95.81/95.85</td>
<td>5.41/4.21</td>
<td>51.24/64.90</td>
</tr>
<tr>
<td>85–89</td>
<td>27 547/46 335</td>
<td>14 160/429</td>
<td>99.79/98.09</td>
<td>4.98/3.66</td>
<td>56.91/69.24</td>
</tr>
<tr>
<td>≥90</td>
<td>13 282/30 034</td>
<td>2 944/22</td>
<td>99.90/98.51</td>
<td>4.59/3.39</td>
<td>58.92/68.08</td>
</tr>
</tbody>
</table>
were considered: (1) Yearly frequency of all medicine use; (2) Yearly frequency of DIM use: acute (1–7 days), subacute (8–29 days) and chronic or regular use (≥ 30 days); (3) Yearly frequency of daily use of at least one DIM and (4) Number and means of different DIM taken within 2015.

All analyses were made considering age and gender distributions.

Ethics Review Board approval was obtained (Reference number PI 16–387, approved on 17 March 2016).

Statistical analysis
All values are given as percentages (frequencies) with a 95% CI or as the mean±SD. For comparisons, Student’s t-test was used for continuous variables and Pearson’s χ² test for categorical variables. A two-tailed p<0.05 was considered to be significant. All statistical analyses were performed using SPSS V.23.0.

RESULTS
Descriptive mapping
A total of 48 858 588 medicines were dispensed in 2015. Approximately three of four people took a medicinal product in 2015, with more women than men taking the product (78.4% vs 68.8%, p<0.05), and this fraction increased with age (table 1).

One of three (34.4%, 95% CI 34.3% to 34.5%) consumed DIM in 2015, again more frequently among women (40.3% vs 28.3%, p<0.05), and this also increased with age. A majority needed to use these medicines on a regular basis (chronic use: 22.5%), while the use for a few days or weeks accounted for 5.3% and 6.6%, respectively, with similar patterns of use by age and gender (table 1).

However, if the distribution is performed with respect to the drivers’ license census, 25.4% (95% CI 25.3% to 25.43%) of people took DIM in 2015, with more men than women (26.5% vs 23.7%, p<0.05) and mostly took DIM regularly (chronic use: 15.3%, 95% CI 15.2% to 15.32%; subacute use: 5.96%, 95% CI 5.92% to 5.99%; acute use: 4.14%, 95% CI 4.11% to 4.18%).

Figure 1 and table 1 show those who used DIM in 2015, their distribution by age and gender, and relation to the drivers’ license census. Age trends differed between the sexes with consumption dropping dramatically among female drivers from 60 years of age and male drivers using less DIM over 75 years of age.

At least one DIM was consumed daily by 5.6% (95% CI 5.52% to 5.58%) of people and by 3.7% (95% CI 3.67% to 3.73% of licensed drivers.

On average (table 2), each person taking DIM took 2.3 medicines (2.1 according to the drivers’ license census data). Acute and subacute consumers (97.5% and 69.1%, respectively) took only one DIM, while chronic consumers (71.5%) took two DIM or more (mean number of DIM use: 2.8). Trends between sexes were similar when the drivers’ license census data were analysed (table 2).

Types of DIM consumed
Of the 10 862 138 DIM dispensed, 9 102 052 (83.8%) belonged to the ATC classification group N (nervous system), 1 176 864 (10.8%) to group A (alimentary tract and metabolism) and 160 631 (1.5%) to group R (respiratory system). ATC group N medicines were prescribed to 29.2% of the population (21.3% regarding the drivers’ license census), group A medicines to 5.4% (4% for drivers) and group R medicines to 4% (2.3% for drivers) (table 3).

Interestingly, ATC groups N, A and R were more frequently prescribed to women than men, all people considered. When considering licensed drivers, the trends showed no differences. Table 4 shows DIM used for several days or weeks and chronically.

DISCUSSION
A detailed description of the consumption of DIM in the general population from Castile and León in 2015 is provided. DIM were consumed by 34.4% (95% CI 34.3% to 34.5%) of the general population and more commonly on a regular basis (22.5%). However, the use for several days (5.3%) or a few weeks (6.6%) should not be neglected. The consumption of DIM increased in line with age. Acute and subacute consumers took at least one DIM and chronic users took nearly three. Of all DIM dispensed, 83.8% belong to the ATC classification group N (nervous system), which were dispensed to 29.2% of the population. Similar trends were found regarding the distribution of licensed drivers by gender but not by age.

The DRUID project provides information on the prevalence of use in Europe of some types of medicines randomly detected in drivers. Of all positive matches (1.36%), benzodiazepines (0.9%), Z-drugs (0.12%) and opioids (0.35%) were frequently confirmed. Furthermore, there is information for other developed countries on the consumption of alcohol, illicit drugs and certain medicines by people injured/killed in road traffic accidents. The DRUID study conducted on injured (seriously injured or killed) people in nine European countries did not produce a clear picture of the use of medicines (and illicit drugs), but combined use of alcohol with medicines (and/or illicit drugs) was shown to be much more common in drivers who had accidents than in the driving population. Although progress has been made in understanding this social and medical problem of driving under the effects of medicines, the available data enable only a partial view of the problem, as only several groups of DIM (mainly psychotropic drugs) have been analysed in blood and oral fluid specimens from drivers. There has also been an attempt to estimate DIM consumption based on dispensed medicines or using driver consumption surveys. Our study provides a detailed overview of all DIM used by the general population, and to the best of our knowledge, this study is the first on this matter.

The combined use of DIM with alcohol is well known to have marked effects on psychomotor performance.
Furthermore, the risk of being seriously injured or killed while driving with these psychoactive substances was highly increased with multiple use and the risk increased severely with combined use with alcohol.\textsuperscript{1, 36} Avoiding use of alcohol is a priority for safe driving,\textsuperscript{1, 6} but particularly for those who take medicines, either acutely or regularly.

One of three used DIM in 2015. Importantly, acute users represented a sizeable proportion of all drivers consuming DIM (5.3%). The effect of medications on driving is more relevant in the first days of use.\textsuperscript{38, 39} Drivers consuming DIM for few days might therefore be the most affected, particularly those taking more than...
One medicine, and this must be taken into account. In addition, multiple daily dosing is an important factor to consider,⁷ especially for drivers over 50 years old.⁹

More than two DIM were dispensed (drivers and non-drivers), particularly to chronic users who took nearly three. In addition, approximately 6% of people consumed at least one DIM daily during the year 2015. Impairment of driving seems to diminish with chronic/stable DIM use,⁹ probably due to tolerance.⁴¹ However, clinical explorations of fitness to drive under the effects of DIM should be performed.⁴¹ Tolerance is a problem that has not been completely assessed and what occurs when more than one medicine is consumed has also not been analysed. A higher prevalence of regular and daily use of DIM are not uncommon in Spain and other developed countries. Therefore our results provide an epidemiological view of the current impact of medicine use patterns that highlight the importance of daily regimens, as well as the importance for elderly acute users.

Our results showed that several types of medicines are prescribed more often than others. ATC group N medicines were prescribed with predilection, mostly to women. This finding was corroborated by the study of Ravera et al.⁵ The finding of frequent DIM use was not surprising, as 20% of the granted medicines (402 of 2013) in Spain are DIM (with the pictogram ‘medicines and driving’ on the packaging). In addition, 83.8% of dispensed DIM in Castile and León were ATC group N medicines (178 of the 2013). These results of DIM use in Defined Daily Doses per 1000 inhabitants day⁴⁸ ⁴⁹ do not differ from other areas in Spain (as measured in Defined Daily Doses per 1000 inhabitants day)⁴⁸ ⁴⁹ and are in line with those reported in other countries.⁰ Recently, Eurostat reported on medicine use in the European Union.⁴⁰ In the European health interview survey, conducted between 2013 and 2015, people were asked about self-reported medicine use. Our data by gender and age range agree well with these results, although figures
### Table 3  Frequency of the consumption of driving-impairing medicines by ATC group

<table>
<thead>
<tr>
<th>ATC groups</th>
<th>Patients under treatment % (95% CI)</th>
<th>Drivers under treatment % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>A</td>
<td>5.3 (5.26 to 5.34)</td>
<td>5.5 (5.46 to 5.54)</td>
</tr>
<tr>
<td>C</td>
<td>0.36 (0.35 to 0.37)</td>
<td>0.26 (0.25 to 0.26)</td>
</tr>
<tr>
<td>D</td>
<td>0.12 (0.12 to 0.13)</td>
<td>0.11 (0.1 to 0.11)</td>
</tr>
<tr>
<td>G</td>
<td>0.6 (0.59 to 0.62)</td>
<td>1 (0.99 to 1.02)</td>
</tr>
<tr>
<td>J</td>
<td>0.02 (0.02 to 0.03)</td>
<td>0.03 (0.03 to 0.04)</td>
</tr>
<tr>
<td>L</td>
<td>0.51 (0.49 to 0.52)</td>
<td>0.07 (0.06 to 0.07)</td>
</tr>
<tr>
<td>M</td>
<td>0.7 (0.69 to 0.72)</td>
<td>1.11 (1.09 to 1.13)</td>
</tr>
<tr>
<td>N</td>
<td>22.45 (22.37 to 22.52)</td>
<td>35.68 (35.6 to 35.77)</td>
</tr>
<tr>
<td>P</td>
<td>0.08 (0.07 to 0.08)</td>
<td>0.24 (0.23 to 0.25)</td>
</tr>
<tr>
<td>R</td>
<td>3.62 (3.59 to 3.65)</td>
<td>4.38 (4.34 to 4.41)</td>
</tr>
<tr>
<td>S</td>
<td>0.41 (0.4 to 0.42)</td>
<td>0.42 (0.41 to 0.43)</td>
</tr>
<tr>
<td>V</td>
<td>0 (0 to 0)</td>
<td>0 (0 to 0)</td>
</tr>
</tbody>
</table>

A, alimentary tract and metabolism; ATC, Anatomical Therapeutic Chemical Classification System; C, cardiovascular system; D, dermatologicals; G, genitourinary system and sex hormones; J, antinecotics for systemic use; L, antineoplastic and immunomodulating agents; M, musculoskeletal system; N, nervous system; P, antiparasitic products, insecticides and repellents; R, respiratory system; S, sensory organs; V, various.
### Table 4 Frequency of the consumption of driving-impairing medicines A, N and R ATC group

<table>
<thead>
<tr>
<th>ATC group</th>
<th>Frequency of use</th>
<th>Patients under treatment</th>
<th>Drivers under treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>% (95% CI)</td>
<td>% (95% CI)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>A</td>
<td>Acute</td>
<td>0.68 (0.61 to 0.74)</td>
<td>1.53 (1.44 to 1.62)</td>
</tr>
<tr>
<td></td>
<td>Subacute</td>
<td>17.7 (17.4 to 18)</td>
<td>29.63 (29.28 to 29.98)</td>
</tr>
<tr>
<td></td>
<td>Chronic</td>
<td>81.62 (81.32 to 81.93)</td>
<td>68.84 (68.49 to 69.19)</td>
</tr>
<tr>
<td>N</td>
<td>Acute</td>
<td>18.06 (17.92 to 18.21)</td>
<td>12.79 (12.69 to 12.89)</td>
</tr>
<tr>
<td></td>
<td>Subacute</td>
<td>21.6 (21.44 to 21.76)</td>
<td>18.8 (18.68 to 18.91)</td>
</tr>
<tr>
<td></td>
<td>Chronic</td>
<td>60.33 (60.15 to 60.52)</td>
<td>68.41 (68.27 to 68.55)</td>
</tr>
<tr>
<td>R</td>
<td>Acute</td>
<td>71.93 (71.75 to 72.36)</td>
<td>74.38 (74.01 to 74.76)</td>
</tr>
<tr>
<td></td>
<td>Subacute</td>
<td>22.63 (22.24 to 23.03)</td>
<td>21.93 (21.57 to 22.28)</td>
</tr>
<tr>
<td></td>
<td>Chronic</td>
<td>5.43 (5.22 to 5.65)</td>
<td>3.69 (3.53 to 3.85)</td>
</tr>
</tbody>
</table>

A, alimentary tract and metabolism; ATC, Anatomical Therapeutic Chemical Classification System; N, nervous system; R, respiratory system.

The use of DIM was frequent in the general population, based on the findings of Castile and Leon in 2015. Chronic use (30 days or more) was common, but acute use (1–7 days) and subacute use (8–29 days) must not be overlooked because they might be the most relevant.

**CONCLUSIONS**

The use of DIM was frequent in the general population, based on the findings of Castile and Leon in 2015. Chronic use (30 days or more) was common, but acute use (1–7 days) and subacute use (8–29 days) must not be overlooked because they might be the most relevant.

The use of DIM was frequent in the general population, based on the findings of Castile and Leon in 2015. Chronic use (30 days or more) was common, but acute use (1–7 days) and subacute use (8–29 days) must not be overlooked because they might be the most relevant.

The use of DIM was frequent in the general population, based on the findings of Castile and Leon in 2015. Chronic use (30 days or more) was common, but acute use (1–7 days) and subacute use (8–29 days) must not be overlooked because they might be the most relevant.

The use of DIM was frequent in the general population, based on the findings of Castile and Leon in 2015. Chronic use (30 days or more) was common, but acute use (1–7 days) and subacute use (8–29 days) must not be overlooked because they might be the most relevant.

The use of DIM was frequent in the general population, based on the findings of Castile and Leon in 2015. Chronic use (30 days or more) was common, but acute use (1–7 days) and subacute use (8–29 days) must not be overlooked because they might be the most relevant.
regarding DIM consumption and risks. ATC group N medicines were the most frequently prescribed.

There is a need worldwide to improve interventions in the field of medicines and driving,\(^1,4,6\) Interventions have been suggested for such populations as the general public (information, awareness of risks for DIM use on driving),\(^1,4,5\) for health authorities/industry leaflets,\(^2,3,4,5\) and for road safety policy-makers.\(^1,6,4,5\) Product labelling systems and inserted patient information,\(^1,5,6\) for health provider systems (prescribing and dispensing software tools),\(^1,6,4,5\) and for road safety policy-makers.\(^1,6,4,5\)

Contributors FJA conceived the study design. EG-A conducted the study. EG-A, FH-G, PC-E and FJA analysed the data, contributed to the interpretation of the results and wrote the manuscript. All authors reviewed and approved the final version of the manuscript.

Funding This work was supported by the Instituto de Salud Carlos III, Redes Temáticas de Investigación Cooperativa, Red de Trastornos Adictivos, grant number RD16/0017/0006, co-funded by FEDER funds of European Union—a way to build Europe.

Competing interests None declared.

Ethics approval CEIC Area de Salud Valladolid Este, Ethic Review Board approval was obtained (Reference number PI 16-387, approved on March 17th, 2016).

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement No additional data are available.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

32. CONCYLIA. Sistema de Información de Farmacia. Gerencia Regional de Salud de Castilla y León. Valladolid, Spain: Junta de Castilla y León.